

Summary of DHCS Medi-Cal Provider Bulletins – July 2025

The Department of Health Care Services (DHCS) issued Medi-Cal bulletins during **July 2025** with updates on the below topics. We are sharing this update with you to ensure you are aware of the information, and you can apply the information to your practice or facility operations, where appropriate.

General Medicine

- 1. 2025 HCPCS Quarter 3 Update
- 2. TAR Requirements for Subacute Care Programs
- 3. Cell and Gene Therapy Policy Updates and New Manual Sections
- 4. Additional Gene Tests Covered under CPT Code 81403
- 5. HCPCS Code G0561 Benefit Status Change
- 6. Additional Dyadic Modifiers Added to Existing Dyadic Service Billing Codes
- 7. Policy Updates for Auditory Osseointegrated Implant CPT Codes
- 8. Provider Manual Revisions
 - a. ev woman (48); inject drug e (73, 74, 75 81); inject drug j-l (20 26, 27-33); medne non (1-2); modif used (15); non ph (17); path an over (9, 10); path blood (1); preg com (8); preg com exc (2); preg com lis (1); prop lab (6, 17, 65)

For information about the above changes, please refer to: <u>Medi-Cal Update - General Medicine</u> <u>July 2025</u> Bulletin 613

Psychological Service

9. Additional Dyadic Modifiers Added to Existing Dyadic Service Billing Codes

For information about the above changes, please refer to: Medi-Cal Update -Psychological Service July 2025 Bulletin 598

Long Term Care

10. 2025 Nursing Facilities – Level A Reimbursement Rate Update

For information about the above changes, please refer to: Medi-Cal Update -Long Term Care July 2025 Bulletin 581

Reminders:

- Providers should bill using valid Medi-Cal codes and following Medi-Cal guidelines for modifiers. Please visit the dhcs.ca.gov website for detailed billing and rate information.
- Clinical Laboratory Improvement Act (CLIA) certification number (10-digit code) is required in box 23 of CMS-1500 claim form.

blueshieldca.com/promise

- Laboratories should regularly monitor the <u>CMS website</u> for new CLIA regulatory requirements.
- Blue Shield Promise requires the JW modifier (indicator of single dose container drug waste) when submitting drug claims.
- For billing and diagnostic purposes, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal Infections (PANDAS) shall be coded as other and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) shall be coded as autoimmune encephalitis until the American Medical Association and the federal Centers for Medicare and Medicaid Services create and assign a specific code or codes. At this time, DHCS recommends using these diagnosis codes:
 - o PANDAS: D89.89, which is used for "other specified disorders involving the immune mechanism, not elsewhere classified"
 - o PANS: D89.9, which is used for "disorder involving the immune mechanism, unspecified"

If you have questions about applying a benefit to Blue Shield of California Promise Health Plan members, please call our Provider Customer Service Department at **(800) 468-9935** from 6 a.m. to 6:30 p.m., Monday through Friday.